Known targets — ChEMBL curated mechanism
ADRA2AADRA2BADRA2CADRB2AGTR1AVPR1AAVPR1BAVPR2BDKRB2CALCRCHRNA3CHRNB4ESR1ESR2GHSRGNRHRGSC1HSPA8MALT1MC1RMC4RNOS1NOS2NOS3OPRK1OXTRRAMP1RAMP2RAMP3SCN5ASSTR1SSTR2SSTR3SSTR4SSTR5dacAdacBdacCfolPftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Carnitine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A16 | Q86VW1 | 1/20 | 0.87 |
| ▸ | MAPT | P10636 | 2/20 | 0.59 |
| ▸ | CPT2 | P23786 | 2/20 | 0.55 |
| ▸ | CPT1A | P50416 | 2/20 | 0.55 |
| ▸ | MEN1 | O00255 | 3/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | HRH1 | P35367 | 1/20 | 0.53 |
| ▸ | CRAT | P43155 | 1/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.46 |
| ▸ | RECQL | P46063 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | CA4 | P22748 | 1/20 | 0.39 |
| ▸ | SLC25A20 | O43772 | 3/20 | 0.39 |
| ▸ | TP53 | P04637 | 2/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | CPT1B | Q92523 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Levocarnitine SCHEMBL7607823 | 1.00 | SLC22A16 (0.87) | SLC22A16MAPTCPT2CPT1AMEN1 | |
| Carnitine SCHEMBL28744379 | 0.98 | SLC22A16 (0.83) | SLC22A16MAPTCPT2CPT1AMEN1 | |
| Carnitine SCHEMBL29036059 | 0.93 | SLC22A16 (0.91) | SLC22A16MAPTCPT2CPT1AMEN1 | |
| Carnitine SCHEMBL1813524 | 0.93 | SLC22A16 (1.00) | SLC22A16MAPTCPT2CPT1AMEN1 | |
| Carnitine SCHEMBL21971 | 0.93 | SLC22A16 (1.00) | SLC22A16MAPTCPT2CPT1AMEN1 | |
| Levocarnitine SCHEMBL21970 | 0.93 | SLC22A16 (1.00) | SLC22A16MAPTCPT2CPT1AMEN1 | |
| D-Carnitine SCHEMBL94286 | 0.93 | SLC22A16 (1.00) | SLC22A16MAPTCPT2CPT1AMEN1 | |
| Carnitine SCHEMBL3902633 | 0.93 | SLC22A16 (1.00) | SLC22A16MAPTCPT2CPT1AMEN1 | |
| Carnitine SCHEMBL17629811 | 0.93 | SLC22A16 (1.00) | SLC22A16MAPTCPT2CPT1AMEN1 | |
| Levocarnitine SCHEMBL4593172 | 0.93 | SLC22A16 (1.00) | SLC22A16MAPTCPT2CPT1AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150273066-A1 | CONVENIENTLY IMPLANTABLE SUSTAINED RELEASE DRUG COMPOSITIONS | RAMSCOR INC (US) | 2015-10-01 | — | — | US | claimed |
| US-20080038316-A1 | Conveniently implantable sustained release drug compositions | RAMSCOR, INC. | 2008-02-14 | — | — | US | claimed |
| CN-1791615-A | A process for the preparation of hydroxy polymer esters and their use | CIBA SC HOLDING AG (CH) | 2006-06-21 | — | — | CN | claimed |
| US-20020106388-A1 | Formulation of flavones and isoflavones for treatment of cellulite | PUGLIESE PETER T (US) | 2002-08-08 | — | — | US | claimed |
| US-12441959-B2 | Composition containing organic ammonium salt | MIYOSHI OIL & FAT CO., LTD. (JP) | 2025-10-14 | — | — | US | disclosed |
| CN-117783352-A | Method for early identifying high-quality sexual precocity stud ram population | 贵州省畜牧兽医研究所 | 2024-03-29 | — | — | CN | disclosed |
| US-20220098515-A1 | COMPOSITION CONTAINING ORGANIC AMMONIUM SALT | MIYOSHI OIL & FAT CO., LTD. (JP) | 2022-03-31 | — | — | US | disclosed |
| EP-3925672-A1 | COMPOSITION CONTAINING ORGANIC AMMONIUM SALT | Miyoshi Oil & Fat Co., Ltd. (JP) | 2021-12-22 | — | — | EP | disclosed |
| CN-113423800-A | Compositions comprising organic ammonium salts | 三吉油脂株式会社 | 2021-09-21 | — | — | CN | disclosed |
| US-10744202-B2 | Sustained release eye drop formulations | RAMSCOR, INC. (US) | 2020-08-18 | — | — | US | disclosed |
| CN-103221038-B | The protective coating of acidic active component | 巴斯夫欧洲公司 | 2019-05-07 | — | — | CN | disclosed |
| US-20180289810-A1 | SUSTAINED RELEASE EYE DROP FORMULATIONS | RAMSCOR, INC. (US) | 2018-10-11 | — | — | US | disclosed |
| CN-101304965-A | Process for producing carnitinamide | MITSUBISHI GAS CHEMICAL CO (JP) | 2008-11-12 | — | — | CN | disclosed |
| EP-1930314-A1 | PROCESS FOR PRODUCING CARNITINAMIDE | MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) | 2008-06-11 | — | — | EP | disclosed |
| EP-1194139-B1 | NUTRITIONAL COMPOSITION FOR WEIGHT MANAGEMENT | IAMS COMPANY (US) | 2008-02-27 | — | — | EP | disclosed |
| US-20080038316-A1 | Conveniently implantable sustained release drug compositions | RAMSCOR, INC. | 2008-02-14 | — | — | US | disclosed |
| CN-1791615-A | A process for the preparation of hydroxy polymer esters and their use | CIBA SC HOLDING AG (CH) | 2006-06-21 | — | — | CN | disclosed |
| US-7001618-B1 | Nutritional composition for weight management | THE IAMS COMPANY (US) | 2006-02-21 | — | — | US | disclosed |
| EP-1194139-A1 | NUTRITIONAL COMPOSITION FOR WEIGHT MANAGEMENT | THE IAMS COMPANY (US) | 2002-04-10 | — | — | EP | disclosed |
| WO-2001003691-A1 | NUTRITIONAL COMPOSITION FOR WEIGHT MANAGEMENT | THE IAMS COMPANY (US) | 2001-01-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12441959-B2 | Composition containing organic ammonium salt | SLC6A15, SLC38A7, SLC6A19 | SLC22A16 147/4885MAPT 1640/4885CPT2 2453/4885 |
| US-20220098515-A1 | COMPOSITION CONTAINING ORGANIC AMMONIUM SALT | SLC6A15, SLC38A7, SLC6A19 | SLC22A16 147/4885MAPT 1640/4885CPT2 2453/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.